Malignant progression of normal tissue is typically driven by complex networks of somatic 13 changes, including genetic mutations, copy number aberrations, epigenetic changes, and 14 transcriptional reprogramming. To delineate aberrant multi-omic tumor features that correlate with 15 clinical outcomes, we present a novel pathway-centric tool based on the multiple factor analysis 16 framework called padma. Using a multi-omic consensus representation, padma quantifies and 17 characterizes individualized pathway-specific multi-omic deviations and their underlying drivers, 18 with respect to the sampled population. We demonstrate the utility of padma to correlate patient 19 outcomes with complex genetic, epigenetic, and transcriptomic perturbations in clinically 20 actionable pathways in breast and lung cancer. 21 22 Keywords: Multi-omic data, multiple factor analysis, pathways, cancer genomics 23 24 25 26
Atlas (TCGA) 1 and Trans-omics for Precision Medicine (TOPMed) program. The increasing 31 emergence of multi-omic data has in turn led to a renewed interest in multivariate, multi-table 32 approaches 2 to account for interdependencies within and across data types 3 . In such large-scale 33 multi-level data, there is often limited or incomplete a priori knowledge of relevant phenotype 34 groups for comparisons, and a primary goal may be to identify subsets of individuals that share 35 common molecular characteristics, design therapies in the context of personalized medicine, or 36 identify relevant biological pathways for follow-up. With these goals in mind, many multivariate 37 approaches have the advantage of being unsupervised, using matched or partially matched omics 38 data across genes, obviating the need for predefined groups for comparison as in the framework 39 of standard differential analyses. A variety of such approaches has been proposed in recent 40 years. For example, Multi-omics Factor Analysis (MOFA) uses group factor analysis to infer sets 41 of hidden factors that capture biological and technical variability for downstream use in sample 42 clustering, data imputation, and sample outlier detection 4 . 43
44
In multi-omic integrative analyses, an intuitive first approach is to consider a gene-centric analysis, 45 as we previously proposed in the EDGE in TCGA tool 5 . Expanding such analyses to the pathway-46 level is also of great interest, as it can lead to improved biological interpretability as well as 47 reduced or condensed gene lists to facilitate the generation of relevant hypotheses. In particular, 48 our goal is to define a method that quantifies an individual's deviation from a sample average, at 49 the pathway-level, while simultaneously accounting for multiple layers of molecular information. 50
Several related approaches for pathway-specific single-sample analyses have been proposed in 51 recent years 6-8 . For example, PARADIGM 7 is a widely used approach based on structured 52 3 probabilistic factor graphs to prioritize relevant pathways involved in cancer progression as well 53 as identify patient-specific alterations; both pathway structures and multi-omic relationships are 54 hard-coded directly in the model, but it requires a discretization of the data and is now a closed-55 source software, making extensions and application to other gene sets difficult. Pathway 56 relevance ranking 9 integrates binarized tumor-related omics data into a comprehensive network 57 representation of genes, patient samples, and prior knowledge to calculate the relevance of a 58 given pathway to a set of individuals. A pathway-centric supervised principal component-based 59 analysis implemented in pathwayPCA 10 performs gene selection and estimates latent variables 60 for association testing with respect to binary, continuous, and survival outcomes within each set 61 of omics data independently. Pathifier 6 instead seeks to calculate a personal pathway 62 deregulation score (PDS), based on the distance of a single individual from the median reference 63 sample on a principal curve; this principal curve approach is analogous to a nonlinear principal 64 components analysis (PCA), but can be applied only to a single-omic dataset (e.g., gene 65 expression). For both PARADIGM and Pathifier, clusters of scores across pathways are shown 66 to correlate with clinically relevant clustering of patients. 67
68
Here, we extend the basic philosophy of the Pathifier approach to multi-omics data, using an 69 innovative application of a Multiple Factor Analysis (MFA), to quantify individualized pathway 70 deviation scores. In particular, we propose an approach called padma ("PAthway Deviation scores 71 using Multiple factor Analysis") to characterize individuals with aberrant multi-omic profiles for a 72 given pathway of interest and to quantify this deviation with respect to the sampled population 73 using a multi-omic consensus representation. We further investigate the following succession of 74 questions. In which pathways are high deviation scores strongly associated with measures of 75 poor prognosis? For such pathways, which specific individuals are characterized by the most 76 highly aberrant multi-omic profile? And for such individuals, which specific genes and omics drive 77 large pathway deviation scores? By providing graphical and numerical outputs to address these 78 questions, padma represents both an approach for generating hypotheses as well as an 79 exploratory data analysis tool for identifying individuals and genes/omics of potential interest for 80 a given pathway. 81
82
There is already some precedent for using MFA to integrate multi-omic data, although existing 83 approaches differ from that proposed here. For instance, de Tayrac et al. suggested using MFA 84 for paired CGH array and microarray data, superimposed with functional gene ontology terms, to 85 highlight common structures and provide graphical outputs to better understand the relationships 86 between omics 11 . In addition, padma shares some similarities with a recently proposed integrative 87 multi-omics unsupervised gene set analysis called mogsa, which is similarly based on a MFA 12 . 88
By calculating an integrated multi-omics enrichment score for a given gene set with respect to the 89 full gene list, mogsa identifies gene sets driven by features that explain a large proportion of the 90 global correlated information among different omics. In addition, these integrated enrichment 91 scores can be decomposed by omic and used to identify differentially expressed gene sets or 92 reveal biological pathways with correlated profiles across multiple complex data sets. However, 93 the fundamental difference in the two approaches is that mogsa evaluates pathway-specific 94 enrichment with respect to the entire set of genes, while padma instead focuses on identifying 95 and quantifying pathway-specific multi-omic deviations between each individual and the sampled 96 quantitative data tables are to be simultaneously analyzed [13] [14] [15] [16] . As such, MFA is a dimension 106 reduction method that decomposes the set of features from a given gene set into a lower 107 dimension space. In particular, the MFA approach weights each table individually to ensure that 108 tables with more features or those on a different scale do not dominate the analysis; all features 109 within a given table are given the same weight. These weights are chosen such that the first 110 eigenvalue of a PCA performed on each weighted table is equal to 1, ensuring that all tables play 111 an equal role in the global multi-table analysis. According to the desired focus of the analysis, 112 data can be structured either with molecular assays (e.g., RNA-seq, methylation, miRNA-seq, 113 copy number alterations) as tables (and genes as features within omics), or with genes as tables 114 (and molecular assays as features within genes). The MFA weights balance the contributions of 115 each omic or of each gene, respectively. In this work, we focus on the latter strategy in order to 116 allow different omics to contribute to a varying degree depending on the chosen pathway. In 117 addition, we note that because the MFA is performed on standardized features, simple differences 118 in scale between omics (e.g., RNA-seq log-normalized counts versus methylation logit-119 transformed beta values) do not impact the analysis. 120 121 More precisely, consider a pathway or gene set composed of p genes ( Figure 1A ), each of which 122 is measured using up to k molecular assays (e.g., RNA-seq, methylation, miRNA-seq, copy 123 number alterations), contained in the set of gene-specific matrices 1 , . . . , that have the same 124 n matched individuals (rows) and 1 , . . . , potentially unmatched variables (columns) in each, 125 where ∈ {1, . . . , } for each gene = 1, . . . , . Because only the observations and not the 126 variables are matched across data tables, genes may be represented by potentially different 127 subset of omics data (e.g., only expression data for one gene, and expression and methylation 128 data for another). 129 6 130
In the first step, these data tables are generally standardized (i.e., centered and scaled). Next, an 131 individual PCA is performed using singular value decomposition for each gene table , and its 132 largest singular value 1 is calculated ( Figure 1B ). Then, all features in each gene table are 133 weighted by The MFA thus provides a consensus across-gene representation of the individuals for a given 145 pathway, and the global PCA performed on the weighted gene tables decomposes the consensus 146 variance into orthogonal variables (i.e., principal components) that are ordered by the proportion 147 of variance explained by each. The coordinates of each individual on these components, also 148 referred to as factor scores, can be used to produce factor maps to represent individuals in this 149 consensus space such that smaller distances reflect greater similarities among individuals. In 150 addition, partial factor scores, which represent the position of individuals in the consensus for a 151
given gene, can also be represented in the consensus factor map; the average of partial factor 152 scores across all dimensions and genes for a given individual corresponds to the factor score 153 7 ( Figure 1D ). A more thorough discussion of the MFA, as well as its relationship to a PCA, may be 154 In the consensus space obtained from the MFA, the origin represents the "average" pathway 173 behavior across genes, omics, and individuals; individuals that are projected to increasingly 174 8 distant points in the factor map represent those with increasingly aberrant values, with respect to 175 this average, for one or more of the omics measures for one or more genes in the pathway. To 176 quantify these aberrant individuals, we propose an individualized pathway deviation score 177 based on the multidimensional Euclidean distance of the MFA component loadings for each 178 individual to the origin: 179
where , corresponds to the MFA factor score of individual i in component l, and L corresponds 181 to the rank of * . Note that this corresponds to the weighted Euclidean distance of the scaled 182 multi-omic data (for the genes in a given pathway) of each individual to the origin. These 183 individualized pathway deviation scores are thus nonnegative, where smaller values represent 184 individuals for whom the average multi-omic pathway variation is close to the average, while larger 185 scores represent individuals with increasingly aberrant multi-omic pathway variation with respect 186 to the average. An individual with a large pathway deviation score is thus characterized by one or 187 more genes, with one or more omic measures, that explain a large proportion of the global 188 correlated information across the full pathway. 189 190 Note that the full set of components is used for this deviation calculation, rather than subsetting 191 to an optimal number of components; we remark that due to their small variance relative to lower 192 dimensions, components from larger dimensions contribute relatively little to the overall pathway 193 deviation scores. Finally, to facilitate comparisons of scores calculated for pathways of differing 194 sizes (e.g., the number of genes), deviation scores with respect to the origin are normalized for 195 the pathway size. 196
Decomposition of individualized pathway deviation scores into per-gene contributions 197
198 9
In order to quantify the role played by each gene for each individual, we decomposed the 199 individualized pathway deviation scores into gene-level contributions. Recall that the average of 200 partial factor scores across all MFA dimensions corresponds to each individual's factor score. We 201 define the gene-level deviation for a given individual as follows: 202
where as before , corresponds to the MFA factor score of individual i in component l, L 204 corresponds to the rank of * , and , , corresponds to the MFA partial factor score of individual i 205 in gene g in component l. Note that by construction, the contributions of all pathway genes to the 206 overall deviation score sum to 0. In particular, per-gene contributions can take on both negative 207 and positive values according to the extent to which the gene influences the deviation of the 208 overall pathway score from the origin (i.e., the global center of gravity across individuals); large 209 positive values correspond to tables with a large influence on the overall deviation of an individual, 210 while large negative values correspond to genes that tend to be most similar to the global average. 211
In the following, we additionally scale these per-gene scores by the inverse overall pathway score 212 to highlight genes with highly atypical multi-omic measures both with respect to other genes in 213 the pathway and with respect to individuals in the population. The padma approach integrates multi-omic data by mapping omics measures to genes in a given 242 pathway. Although this assignment of values to genes is straightforward for RNA-seq, CNA, and 243 methylation data, a definitive mapping of miRNA-to-gene relationships does not exist, as miRNAs 244 can each potentially target multiple genes. Many methods and databases based on text-mining 245 or bioinformatics-driven approaches exist to predict miRNA-target pairs 18 . Here, we make use of 246 the curated miR-target interaction (MTI) predictions in miRTarBase (version 7.0) 19 , using only 247 11 exact matches for miRNA IDs and target gene symbols and predictions with the "Functional MTI" 248 support type. Although the TCGA data used here have been filtered to include only those genes 249 for which expression measurements are available, there are cases where missing values are 250 recorded in other omics datasets (e.g., when no methylation probe was available in the promoter 251 region of a gene, or when no predicted MTIs were identified) or where a given feature has little or 252 no variance across individuals. In this analysis, features for a given omics dataset were removed The first question we address is the prioritization of pathways that are associated with a given 279 phenotype of interest. After processing the TCGA data and assembling the collection of gene 280 sets, we sought to identify a subset of pathways for which deviation scores were significantly 281 associated with patient outcome, as measured by PFI. To focus on pathways with the largest 282 potential signal (i.e., those for which a small number of individuals have very large deviation 283 scores relative to the remaining individuals) we consider only those with the most highly positively 284 skewed distribution of deviation scores. For each of the top 5% of pathways (n = 57) ranked 285 according to their Pearson's moment coefficient of skewness, we fit a Cox proportional hazards 286 (PH) model for the PFI on the pathway deviation score. Using the Benjamini-Hochberg 22 adjusted 287 p-values from a likelihood ratio test (FDR < 5%), we identified 14 pathways with deviation scores 288 that were significantly associated with the progression-free interval in lung cancer (Table 1; see  289   Supplementary Table 2 for the full gene lists in each pathway); for all of these, higher pathways 290 scores corresponded to a worse survival outcome. Note that the filtering on skewness of the 291 pathway scores is performed completely independently of the survival phenotype, ensuring that 292 the downstream survival analysis is not biased 23 . Of note, while candidates within the majority 293 deviated pathways (Table 1) have been univariately associated with patient outcome (e.g., cell 294 cycle, DNA repair, and apoptosis 24,25 ), the padma TCGA analysis is unique in its ability to extend 295 these associations across multiple gene patient-specific perturbations within a pathway at the 296 genomic and transcriptomic RNA levels. 297 298 13
The detection of several pathways related to DNA repair (ATM, Homologous DNA repair, 299 BRCA1/2-ATR; Table1), as well as cell cycle and apoptosis related pathways, prompted us to 300 consider is whether these pathway deviation scores are simply acting as proxies for the tumor 301 mutational burden (i.e., the total number of nonsynonymous mutations) for each individual. To 302 investigate this, we estimated the mutational burden for each individual by counting the number 303 of somatic nonsynonymous mutations in a set of cancer-specific driver genes (n=183 and n=181 304 genes in breast and lung cancer, respectively) identified by IntOGen 26 . After adding a constant of 305 1 to these counts and log-transforming them, we fit a linear model to evaluate their association 306 with the pathway deviation scores; after correcting p-values from the Wald test statistic for multiple 307 testing (FDR < 10%), no pathways were found to be associated with the mutational burden. In 308 addition, when repeating the Cox PH model described above including the log-mutational burden 309 as an additional covariate, adjusted p-values were generally similar to previous values, and the 310 top six pathways remained significant at a significance threshold of 5%. This suggests that the 311 biological signal contained in the pathway deviation scores is indeed independent of that linked 312 To illustrate the full range of results provided by padma, we focus in particular on the results for 324 the D4-GDP dissociation inhibitor (GDI) signaling pathway. D4-GDI is a negative regulator of the 325 ras-related Rho Family of GTPases, and it has been suggested that it may promote breast cancer 326 cell proliferation and invasiveness 27,28 . The D4-GDI signaling pathway is made up of 13 genes; 327 RNA-seq, methylation, and CNA measures are available for all 13 genes, with the exception of 328 CYCS and PARP1, for which no methylation probes were measured the promoter region. In 329 addition, miRNA-seq data were included for one predicted target pair: hsa-mir-421 ➝ CASP3. 330
Over the 13 genes in the pathway, 130 of the 144 individuals had no nonsynonymous mutations, 331 while 13 and 1 individuals had 1 or 3 such mutations; ARHGAP5 and CASP3 were most often 332 characterized by mutations (3 individuals affected for each). Notably, although the D4-GDI 333 15 pathway has been previously implicated in breast cancer aggressiveness 27,28 , this is to our 334 knowledge the first evidence suggesting that D4-GDI pathway might play a similar role in 335 promoting lung cancer. 336 337 Using the multi-omic data available for the D4-GDI signaling pathway, we can use the outputs of 338 padma to better understand the individualized drivers of multi-omic variation. In particular, it is 339 possible to quantify both gene-specific deviation scores as well as an overall pathway deviation 340 score for each individual, respectively based on the set of partial or full MFA components. We first 341 visualize the scaled gene-specific deviation scores for the top and bottom decile of individuals, 342 according to their overall pathway deviation score ( Figure 2) ; these groups thus correspond to the 343 individuals that are least and most similar to the average individual within the population. We 344 remark that the 10% of individuals with the most aberrant overall scores for the D4-GDI signaling 345 pathway, who also had a high 1-and 5-year mortality rate, are those that also tend to have large 346 aberrant (i.e., red in the heatmap) scaled gene-specific deviation scores for one or more genes. 347 To provide an intuitive link between these gene-specific deviation scores with the original batch-357 corrected multi-omics data that were input into padma, we further focus on the three genes 358 (CASP1, CASP3, and CASP8) for which large deviation scores were observed for the two highly 359 16 aberrant individuals (TCGA-78-7536 and TCGA-78-7155) in the D4-GDI signaling pathway. We 360 plot boxplots of the Z-scores for each available omic for the three genes across all 144 individuals 361 with lung cancer (Figure 3) , specifically highlighting the two aforementioned individuals; full plots 362 of all 13 genes in the pathway are included in Supplementary Figure 1 . This plot reveals that both 363 individuals are indeed notable for their overexpression, with respect to the other individuals, of 364 miRNA hsa-mir-421 ( Figure 3D ), which is predicted to target CASP3; in coherence with this, both 365 individuals had weaker CASP3 expression than average (although we note that its expression 366 was not particularly extreme with respect to the full sample). Individual TCGA-78-7536 appears 367 to have a hypomethylated CASP1 promoter, but a significantly higher number of copies of CASP8, As overall pathway deviation scores represent the multi-dimensional average of these gene-397 specific deviation scores, a deeper investigation into them can also provide useful insight for a 398 given pathway. We first note that the distribution of deviation scores for the D4-GDI signaling 399 pathway ( Figure 4A ) is highly skewed, with a handful of individuals (e.g., TCGA-78-7536, TCGA-400 78-7155, TCGA-91-6847, TCGA-50-5931, TCGA-50-5051, and TCGA-66-7725) characterized by 401 particularly large scores with respect to the remaining individuals. The individual with the most 402 aberrant score for this pathway, TCGA-78-7536, had a single pathway-specific somatic mutation 403 in the CASP1 gene, and a total of 7 cancer-specific driver gene mutations (corresponding to the 404 80th percentile of individuals considered here). Although these pathway deviation scores are 405 calculated across all dimensions of the MFA, it can also be useful to represent individuals in the 406 first few components of the consensus MFA space ( Figure 4B) ; the farther away an individual is 407 from the origin over multiple MFA dimensions, the larger the corresponding pathway deviation 408 score. In this case, we see that TCGA-78-7536 is a large positive and negative outlier in the 409 second (9.55% total variance explained), and third (8.07% total variance explained) MFA 410 components, respectively, although less so in the first component (11.97% total variance 411 explained). In addition, we note that RNA-seq is the major driver of the first MFA dimension 412 (54.38% contribution), while promoter methylation and copy number alterations take a larger role 413 in the second and third dimensions (42.29% and 59.18% contribution, respectively). miRNA 414 expression appears to play a fairly minor role in the MFA, with its maximum contribution (21.14%) 415 occurring at only the 16th dimension. 416
417
When examining the partial factor maps for this individual over the first three MFA dimensions 418 ( Figures 4C-D) , we note the large contribution of CASP3 (axis 1), CASP10 (axis 2), CASP1 and 419 CASP 8 (axis 3), as evidenced by their distance from the origin in these dimensions. Overall, this 420 is coherent with the previous gene-level analyses (Figure 2) , where hypomethylation in CASP1 421 and large copy number gains for CASP3 and CASP8 with respect to the population were identified 422 for this individual. Other individuals with large overall deviation scores (e.g., TCGA-50-5931) are 423 not obvious outliers in the first two MFA dimensions, reflecting the fact that additional dimensions 424 play a more important role for them. Taken together, the individualized gene-specific and overall 425 pathway deviation scores output by padma provide complementary and interesting exploratory 426 insight into atypical multi-omic profiles for a given pathway of interest (here, the D4-GDI signaling 427 pathway in lung cancer). interest; to illustrate the use of padma in such a case, we focus on histological grade for breast 446 cancer. To quantify whether pathway deviation scores tend to be associated with histological 447 grade in breast cancer, we performed a one-way ANOVA on the three measures that comprise 448 histological grade for each of the 1136 pathways. Based on the Benjamini-Hochberg 22 adjusted 449 p-values from an F-test (FDR < 5%), all (1136) or nearly all (1135) pathways were found to have 450 deviation scores that are significantly correlated with mitotic index and nuclear pleomorphism. 451 Intriguingly, no pathways were found to be associated with degree of glandular/tubule formation; 452 this may in part be due to the large proportion of individuals identified as grade III (poorly 453 differentiated) for this measure (n = 285). The rankings of pathways based on mitotic index and 454 nuclear pleomorphism were generally in agreement ( Supplementary Figure 2) . In all but two 455 cases, higher deviation pathway scores corresponded to the higher grades for these two 456 measures, corresponding to more aggressive tumors; the two exceptions were the Presynaptic 457 nicotinic acetylcholine receptor and Highly calcium permeable postsynaptic nicotinic acetylcholine 458 receptor pathways (both from Reactome), for which the largest pathway deviation scores were 459 associated with grade II, rather than grade III, of the mitotic index. 460
461
To prioritize pathways among this list, we calculated the rank product of the individual rankings 462 by p-value for mitosis and nuclear pleomorphism; the top 10 pathways according to this joint 463 ranking are shown in Table 2 (see Supplementary Table 3 for the full gene lists in each pathway). 464
The signaling by Wnt pathway, which is made up of 63 genes, had the highest combined ranking 465 for these two histological measures. Of this set of genes, all had RNA-seq, methylation, and CNA 466 measures available, with the exception of FAM123B and PSMD10 (no CNA measures with 467 nonzero variance) and PSMB1 to PSMB10, PSMC2, PSMC3, PSMC5, PSMC6, PSME1, and 468
